In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.
Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of the year, amid signs of a "return towards normal business
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company.
American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that
Novartis may be planning to sell off its generics business Sandoz, but that hasn't stopped it investing in the unit ahead of a decision on its future later this year.
A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive action by French pharma company Servier will not be reduced, despite an eyebrow-raising bid
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.